Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Domagrozumab (Primary) ; Domagrozumab (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

Most Recent Events

  • 14 Sep 2022 Data from this study and other phase 2 study (NCT02310763) was sought to establish the PK/PD relationship between free domagrozumab and total myostatin concentrations in pediatric patients with DMD using a prior semi-mechanistic model, published in the Clinical Pharmacology and Therapeutics
  • 12 Mar 2016 Population pharmacokinetic/pharmacodynamic model results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top